$MNKD Cashflow Statement | Understand Stock

$MNKD

$3.29 +$0.06 (1.86%) Close

$MNKD Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Stock-based compensation
Interest on liability for sale of future royalties
Sold portion of royalty revenue
Write-off of inventory
Depreciation and amortization
Interest expense on financing liability
Loss (gain) on foreign currency transaction
Impairment loss on available-for-sale investment
Net accretion of investments
Non-cash lease expense of right-of-use assets
Change in fair value of contingent liability
Amortization of debt discount and issuance costs
Asset impairment
Interest on milestone right
Amortization of financing liability
Amortization of right-of-use assets
Gain on bargain purchase
Loss on estimated returns of acquired product
Loss on disposal of fixed assets
Interest on Mann Group convertible note
Other, net
Interest accretion on financing liability
Change in deferred tax liability

Changes in operating assets and liabilities:
Accounts receivable, net
Inventory
Prepaid expenses and other current assets
Other assets
Accounts payable
Accrued expenses and other current liabilities
Deferred revenue
Recognized loss on purchase commitments
Operating lease liabilities
Accrued interest on Mann Group convertible note
Deposits from customer

Net cash provided by operating activities
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of available-for-sale securities
Proceeds from maturities of available-for-sale securities
Acquisition of scPharma, net of cash acquired
Issuance of note receivable
Purchase of property and equipment
Purchase of held-to-maturity securities
Proceeds from maturities of held-to-maturity securities
Proceeds from insurance claim
Net cash used in investing activities
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from term loan
Payment of loan issuance costs
Payments for taxes related to net issuance of common stock associated with restricted stock units and stock options
Principal payments on financing liability
Proceeds from market price stock purchase plan and employee stock purchase plan
Payment on financing liability
Proceeds from Senior convertible notes
Issuance costs associated with Senior convertible notes
Proceeds from the sale-leaseback transaction
Milestone Right Agreement payment
Principal and early extinguishment payments on MidCap credit facility
Proceeds from sale of future royalties
Issuance costs associated with sale of future royalties
Principal and early extinguishment payments on senior convertible notes
Principal and early extinguishment payments on Mann Group convertible note
Payment of MidCap credit facility
Payment on MidCap credit facility
Payment of MidCap credit facility prepayment penalty
Proceeds from at-the-market-offering
Payment of employment taxes related to vested restricted stock units and exercise of stock options
Proceeds from market price stock purchase plan
Issuance costs associated with at-the-market offering
At The Market Issuance
Total issuance costs associated with at-the-market offering

Deposit for the sale-leaseback transaction
Net cash provided by (used in) financing activities

NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF PERIOD
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD
SUPPLEMENTAL CASH FLOWS DISCLOSURES:
Interest paid in cash
Income taxes paid in cash
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Non-cash contingent consideration from acquisition of scPharma
Debt forgiven as part of scPharma acquisition
Payments of senior convertible note principal through common stock issuances
Amortization of liability for sale of future royalties
Reclassification of Midcap credit facility from long-term to current
Reclassification of investments from long-term to current
Purchases of property and equipment included in accounts payable and accrued expenses
Assumption of right-of-use-asset and operating lease liability
Non-cash acquisition of intangible asset
Payments of Mann Group principal and interest through common stock issuances
Non-cash acquisition of property and equipment
Addition of right-of-use-asset and lease liability
Right-of-use asset modification
Goodwill adjustment for a net reduction in liabilities
Receivable for insurance claim on damaged equipment
Accrued issuance costs associated with liability for sale of future royalties
Payments on debt and interest through common stock issuance
Reclassification of Thirona convertible notes and interest receivable from long-term to current
Issuance of common stock under employee stock purchase plan
Premium on convertible note
Addition of right-of-use-asset
Contingent milestone liability

Comments